Clinical Trial Search

Primary: Bacterial Elimination Rate (BER) in the CDI and EI Groups — 100.0; 72.7; 90.0; 87.5 percentage of participants

Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants

Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants

Primary: Incidence of Adverse Events — 1; 1; 0; 1 events

Primary: Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment — 0 neuronal cells/mm^2

Primary: Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration — 0; 0; 3; 2 Participants

Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…

Primary: Blood Test Performance — 18; 17 Participants

Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea

Primary: Development of Diarrhea — 5; 6 participants

Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc

Primary: Number of Participants With Treatment-free Remission at 1 Year After Study Completion — 2 Participants

Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932

Primary: Percentage of Participants With VRE Decolonization — 1; 1 Participants

Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events

Primary: To Evaluate the Effect of BSS on the Human Gut Microbiome. — 2 Number of different bacterial taxa — p=<0.05

Primary: Change in Number of Participants With Post-operative Infectious and Inflammatory Complications — 43; 47; 25; 17 Participants

Primary: Number of Participants With Solicited or Unsolicited Adverse Events — 15; 16; 17; 16 Participants

Primary: Binge Frequency — 10.4; 11.3 Binge Episodes/Week — p=<.05

Primary: Number of Patients Diagnosed With Hirschsprung-associated Enterocolitis (HAEC). — 10; 7 participants — p==0.897

Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants

Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events — 4; 9; 8; 9 Participants

Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants

Primary: Campylobacteriosis — 13; 11 Participants

Primary: Changes to the Urinary Microbiota — 3; 2; 1 participants

Primary: SUVmax of FDG in Each Colonic Segment — 4.6; 4.3 SUV

Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer

Primary: Interleukin 5 Serum Cytokine Level on 0+2 Day — 4; 4 pg/ml — p=0.32

Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants